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A BS TR AC T
BACKGROUND
Hereditary angioedema is characterized by recurrent attacks of angioedema of the 
skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symp-
toms. Icatibant is a selective bradykinin B2 receptor antagonist.
METHODS
In two double-blind, randomized, multicenter trials, we evaluated the effect of 
icatibant in patients with hereditary angioedema presenting with cutaneous or ab-
dominal attacks. In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, 
patients received either icatibant or placebo; in FAST-2, patients received either 
icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days. Icatibant was 
given once, subcutaneously, at a dose of 30 mg. The primary end point was the 
median time to clinically significant relief of symptoms.
RESULTS
A total of 56 and 74 patients underwent randomization in the FAST-1 and FAST-2 
trials, respectively. The primary end point was reached in 2.5 hours with icatibant 
versus 4.6 hours with placebo in the FAST-1 trial (P = 0.14) and in 2.0 hours with 
icatibant versus 12.0 hours with tranexamic acid in the FAST-2 trial (P<0.001). In 
the FAST-1 study, 3 recipients of icatibant and 13 recipients of placebo needed treat-
ment with rescue medication. The median time to first improvement of symptoms, 
as assessed by patients and by investigators, was significantly shorter with icatibant 
in both trials. No icatibant-related serious adverse events were reported.
CONCLUSIONS
In patients with hereditary angioedema having acute attacks, we found a signifi-
cant benefit of icatibant as compared with tranexamic acid in one trial and a non-
significant benefit of icatibant as compared with placebo in the other trial with 
regard to the primary end point. The early use of rescue medication may have ob-
scured the benefit of icatibant in the placebo trial. (Funded by Jerini; ClinicalTrials 
.gov numbers, NCT00097695 and NCT00500656.)
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Hereditary angioedema is an auto-somal dominant disorder caused by a defi-ciency of C1 esterase inhibitor, which has 
a regulatory role in the classic complement pathway 
and in the coagulation, fibrinolytic, and kallikrein–
kinin (contact-system) cascades. Reduced activity 
of C1 esterase inhibitor may result in an elevated 
plasma level of bradykinin,1,2 the key mediator of 
symptoms in hereditary angio edema.3,4
Patients with hereditary angioedema present 
with acute attacks of subcutaneous and submu-
cosal edema that can affect the upper airways, 
face, extremities, genitals, and gastrointestinal 
tract.5-7 Pharyngolaryngeal edema, which is poten-
tially life-threatening because of the risk of upper-
airway obstruction, can also occur.8
Current treatment options for hereditary angio-
edema are limited. Tranexamic acid, an oral anti-
fibrinolytic agent, reportedly improves symptoms 
during acute attacks,9 although its efficacy has not 
been proved in controlled studies. Attenuated an-
drogens can reduce the number and severity of 
attacks when used prophylactically but have impor-
tant adverse effects and are ineffective during acute 
attacks.10-12 Replacement therapy with intrave-
nous C1 esterase–inhibitor concentrate reverses 
acute attacks.13,14 However, formulations of this 
agent are registered in only a few countries.
Icatibant is a selective bradykinin B2 receptor 
antagonist15,16 with, like bradykinin itself, an af-
finity for the B2 receptor. It does not interact with 
bradykinin B1 receptors or other peptide recep-
tors.17 Icatibant reverses increased vascular perme-
ability in C1 esterase inhibitor–knockout mice,18 
inhibits bradykinin-induced vasodilation in hu-
mans,4,19 and, in a phase 1 study, showed dose- 
and time-dependent inhibition of bradykinin-
induced effects in vivo.20 In a phase 2 study, 
symptoms improved significantly after open-label 
treatment with icatibant in 15 patients with he-
reditary angioedema having acute cutaneous or 
abdominal attacks.1
We conducted two phase 3 studies of icatibant 
treatment for acute attacks of angioedema in adults 
with hereditary angioedema due to deficiency of 
the C1 esterase inhibitor. Results from the con-
trolled phase of both studies are presented here.
Me thods
Study Design
The For Angioedema Subcutaneous Treatment 
(FAST)-1 and FAST-2 trials were double-blind, ran-
domized, prospective studies. FAST-1 was placebo-
controlled. In FAST-2, icatibant was compared 
with tranexamic acid. Both were multicenter trials 
(see Table 1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org). 
Each study was approved by the independent eth-
ics committee at each center and was conducted in 
accordance with the Declaration of Helsinki, the 
International Conference on Harmonisation Good 
Clinical Practice guidelines, and current regula-
tory requirements. The complete study protocols 
and statistical-analysis plans are available at 
NEJM.org.
Both trials were designed and sponsored by 
Jerini. Monitoring and data collection were su-
pervised for FAST-1 by Hesperion and Parexel 
International and for FAST-2 by Hesperion and 
Amantec. Data management and statistical anal-
ysis in both trials were performed by Hesperion. 
The academic authors vouch for the accuracy and 
completeness of the data and all analyses, as well 
as the fidelity of the reported information to the 
protocols.
Patients
Before enrollment, inclusion and exclusion criteria 
were assessed in all patients, and all patients gave 
written informed consent. In both trials, the eli-
gibility criteria included an age of 18 years or 
older and a documented diagnosis of hereditary 
angioedema type I (from an antigenic deficiency 
of the C1 esterase inhibitor) or type II (from a 
functional deficiency of the C1 esterase inhibitor). 
Diagnosis was confirmed by a review of the medi-
cal history and a finding of levels of functional or 
antigenic C1 esterase inhibitor of less than half 
the normal levels. For patients receiving andro-
gens, historical laboratory values were used to con-
firm the diagnosis. The main exclusion criteria 
included a diagnosis of angioedema other than 
hereditary angioedema, serious concomitant ill-
ness, and pregnancy or lactation.
After completion of the screening visit, eligible 
patients were asked to return to the study site no 
later than 6 hours after an acute attack of angio-
edema became at least moderately severe, to un-
dergo assessment before randomization. Patients 
were excluded if they had received pain medication 
for the current attack, C1 esterase inhibitor within 
3 days before the attack, or tranexamic acid within 
a week before the attack or if they were receiving 
angiotensin-converting–enzyme inhibitors or were 
pregnant. Patients presenting with cutaneous or 
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abdominal attacks were asked to evaluate the se-
verity of three specific symptoms (cutaneous 
swelling, cutaneous pain, and abdominal pain) 
on a visual-analogue scale. For each symptom, 
patients drew a vertical line on a nongraduated 
100-mm visual-analogue scale, according to se-
verity (with 0 mm indicating no symptoms, and 
100 mm indicating symptoms of the worst pos-
sible severity). Patients with a score on the visual-
analogue scale of at least 30 mm for one or more 
of the three symptoms, and no exclusion criteria, 
were considered to have had an eligible attack.
Study Treatment
Patients with eligible attacks were randomly as-
signed (in a 1:1 ratio and after stratification, with 
the use of stochastic minimization, according to 
study center and the site of edema) to receive ei-
ther subcutaneous icatibant, at a dose of 30 mg, or 
a matched subcutaneous placebo injection (in the 
FAST-1 trial) or oral tranexamic acid at a dose of 
3 g daily for 2 days (in the FAST-2 trial). Blinding 
was maintained in the FAST-1 trial by means of the 
identical appearance of the placebo and in the 
FAST-2 trial by means of a double-dummy design 
(i.e., concomitant administration of placebo cap-
sules or subcutaneous placebo injection). In the 
FAST-2 trial, patients received two further doses of 
oral medication (either tranexamic acid or placebo) 
on day 1, one at 6 hours and one at 12 hours after 
the initial study-drug administration, followed by 
three further doses, each 6 to 8 hours apart, on 
day 2.
In both trials, any patient having a subsequent 
attack of sufficient severity to necessitate treat-
ment was included in an open-label extension 
phase and received icatibant. Patients with poten-
tially life-threatening laryngeal angioedema were 
also treated with open-label icatibant.
Patients were hospitalized for up to 15 hours. 
Symptoms were assessed by patients, using the 
visual-analogue scale, at 30-minute intervals be-
tween 1 and 4 hours after administration of the 
study drug and also at 5, 6, 8, 10, and 12 to 15 
hours after administration. Patients then assessed 
their symptoms three times a day, from day 2 to 
day 5 or until symptoms had subsided. Follow-up 
visits were scheduled for days 2 and 14, week 5, 
and week 24. Blood samples were obtained before 
study-drug administration and on days 1, 2, and 
14, week 5, and week 24 after administration.
Concomitant medication for other conditions 
was permitted if it did not interfere with study 
objectives (see the Supplementary Appendix). Res-
cue therapy (i.e., with C1 esterase inhibitor con-
centrate, antiemetic agents, or opiates) for relief of 
any symptom was permitted but withheld for as 
long as possible (ideally until 8 or 9 hours after 
study-drug administration). Data for patients who 
needed rescue therapy were not censored or ex-
cluded from analyses.
End Points
Based on the highest score on the visual-analogue 
scale before study-drug administration, one of the 
three main symptoms (cutaneous swelling, cuta-
neous pain, or abdominal pain) was defined in 
each patient as the index symptom for purposes 
of assessing the primary end point. For attacks 
with a combination of these symptoms, abdomi-
nal pain was considered the index symptom.
The primary efficacy end point was the medi-
an time to clinically significant relief of the index 
symptom. Clinically significant symptom relief 
was defined as a minimum decrease in the score 
on the visual-analogue scale of 20 to 30 mm, de-
pending on the initial symptom severity. Therefore, 
the decrease in severity necessary to achieve the 
primary end point was at least 30% (i.e., 30-mm 
decrease from a baseline score of 100 mm). This 
decrease had to have been sustained for three con-
secutive measurements on the visual-analogue 
scale, with the first measurement being the time 
point at which clinically significant relief was 
achieved.
Secondary efficacy end points included the me-
dian times to first symptom improvement ac-
cording to the patient and according to the in-
vestigator; the median time to almost complete 
relief of symptoms (i.e., the end of an attack), 
defined as the time point at which the score on 
the visual-analogue scale was 0 to 10 mm for at 
least three consecutive measurements for all 
symptoms, and the proportion of patients reach-
ing the median time to clinically significant relief 
of the index symptom within 4 hours after the 
start of the study drug. Patients receiving open-la-
bel icatibant for laryngeal edema also had their 
symptoms assessed after the start of study treat-
ment, both by themselves and by an investigator 
(see the Supplementary Appendix).
Safety was evaluated by means of adverse-event 
reporting, documentation of local tolerability 
(i.e., injection-site reactions), measurement of vital 
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signs, electrocardiography, clinical laboratory test-
ing, urinalysis, and assessment of complement 
activation. For patients from whom at least one 
serum sample had been obtained after the start 
of the study drug, testing for anti-icatibant anti-
bodies was performed with the use of enzyme-
linked immunosorbent assays.
Statistical Analysis
On the basis of historical data for the patients, we 
estimated that the mean time to clinically signifi-
cant relief of the index symptom for nontreated at-
tacks would be 16.8 hours, with a variance of 44.8 
hours. Using data from the same patients after 
treatment with icatibant in a phase 2 trial,1 we esti-
mated a mean and variance of the time to clini-
cally significant relief with icatibant of 1.9 hours 
and 1.4 hours, respectively. For the power calcula-
tion, variances of 4 hours for icatibant, 46 hours 
for tranexamic acid, and 64 hours for placebo were 
used. For the FAST-1 trial, 20 patients per group 
were needed to provide 80% power to detect a dif-
ference of 5.5 hours in the median time to clini-
cally significant relief between the icatibant group 
and the placebo group in the FAST-1 trial with a 
two-sided type I error of 0.05. For the FAST-2 trial, 
27 patients per group were needed to detect a 
difference in the median time to clinically sig-
nificant relief of 4.0 hours between the icatibant 
group and the tranexamic acid group. After inflat-
ing the sample sizes by 20% to adjust for the use of 
a nonparametric Wilcoxon test, we calculated that 
we would need to enroll 25 and 33 patients per 
group for the FAST-1 trial and FAST-2 trial, respec-
tively. The final sample sizes of 56 and 74 patients, 
respectively, accounted for a projected dropout 
rate of 10%.
The prespecified primary analysis was based 
on the intention-to-treat population, which in-
cluded all patients who underwent randomiza-
tion. Comparisons between groups were per-
formed with the use of the prespecified Wilcoxon 
log-rank test with a two-sided significance level 
of 5%. The Wilcoxon test was used for the time-
to-event analysis. For the primary end point, re-
sults based on the two tests were checked, verified, 
and found to be identical.
All secondary analyses were prespecified. All 
time-to-event data were evaluated as for the pri-
mary analysis. Fisher’s exact test, with 95% confi-
dence intervals calculated for each group by means 
of the Clopper–Pearson method, was used to com-
pare the percentage of patients with clinically sig-
nificant relief of the index symptom at 4 hours 
after the start of the study drug. Two-sided 95% 
confidence intervals for the difference in propor-
tions were calculated with the use of the Ander-
son–Hauck correction.
All reported P values are two-sided and were not 
adjusted for multiple testing. No interim analyses 
were performed. Demographic, safety, and toler-
ability results are reported descriptively.
Table 1. Baseline Characteristics of the Study Patients in the FAST-1 and FAST-2 Trials, According to Study Group.*
Characteristic FAST-1 FAST-2
Icatibant (N = 27) Placebo (N = 29) Icatibant (N = 36) Tranexamic Acid (N = 38)
Sex — no. (%)
Male 11 (41) 8 (28) 12 (33) 15 (39)
Female 16 (59) 21 (72) 24 (67) 23 (61)
Age — yr 34.8±9.8 34.9±11.4 40.4±13.6 41.9±12.4
Weight — kg 80.3±21.1 76.0±21.9 80.1±16.1 74.2±15.6
Type of HAE attack — no.
Cutaneous 14 13 24 23
Abdominal 13 16 12 15
No. of attacks in previous 6 mo — median (range)
Cutaneous 6 (1–44) 6 (1–50) 6 (1–24) 5 (1–25)
Abdominal 3 (1–24) 5 (2–16) 3 (1–15) 3 (1–72)
Cutaneous and abdominal 2 (1–40) 5 (1–12) 4 (1–24) 2 (1–12)
Laryngeal 1 (1–4) 1 (1–9) 2 (1–7) 1 (1–6)
* Plus–minus values are means ±SD. HAE denotes hereditary angioedema.
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R esult s
Patients
In the FAST-1 trial, 178 patients were screened 
and 64 enrolled (Fig. 2 in the Supplementary Ap-
pendix). Of these, 56 were randomly assigned to 
receive icatibant (27 patients) or placebo (29 pa-
tients). In the FAST-2 trial, 247 patients were 
screened and 77 enrolled (Fig. 3 in the Supple-
mentary Appendix). Of these, 74 were randomly 
assigned to receive icatibant (36 patients) or 
tranexamic acid (38 patients). The baseline char-
acteristics were similar between study treatment 
groups in both trials, although the sex ratios dif-
fered in the FAST-1 study (Table 1).
End Points
In FAST-1, the primary end point, the median time 
to clinically significant relief of the index symp-
tom, was 2.5 hours in the icatibant group versus 
4.6 hours in the placebo group (P = 0.14) (Table 2 
and Fig. 1A). In FAST-2, the median time to clin-
ically significant relief of the index symptom was 
2.0 hours with icatibant versus 12.0 hours with 
tranexamic acid (P<0.001) (Table 2 and Fig. 1B). 
The median time to almost complete relief of 
symptoms was 8.5 hours with icatibant versus 19.4 
hours with placebo (P = 0.08) in FAST-1 (Table 2 and 
Fig. 2A) and 10.0 hours with icatibant versus 51.0 
hours with tranexamic acid (P<0.001) in FAST-2 
(Table 2 and Fig. 2B). The percentage of patients 
with clinically significant relief of the index symp-
tom at 4 hours after the start of study treatment 
was 67% in the icatibant group versus 46% in the 
placebo group in FAST-1 (P = 0.18) and 80% in the 
icatibant group versus 31% in the tranexamic acid 
group in FAST-2 (P<0.001) (Table 2).
The median time to first symptom improve-
ment was significantly shorter with icatibant than 
with placebo in FAST-1, as assessed by the patient 
(0.8 vs. 16.9 hours, P<0.001) or the investigator 
(1.0 vs. 5.7 hours, P<0.001) (Table 2). Similarly, 
the median time was significantly shorter with 
icatibant than with tranexamic acid in FAST-2, 
as assessed by the patient (0.8 vs. 7.9 hours, 
P<0.001) or the investigator (1.5 vs. 6.9 hours, 
P<0.001) (Table 2).
Post Hoc Analyses
Several post hoc analyses were undertaken in an 
effort to understand the differences between the 
two studies with respect to the primary end point. 
Table 2. Clinical Outcomes in the FAST-1 and FAST-2 Trials, According to Study Group.*
Outcome FAST-1 FAST-2
Icatibant 
(N = 27)
Placebo 
(N = 29) P Value
Icatibant 
(N = 36)
Tranexamic 
Acid (N = 38) P Value
Time to clinically significant relief of the index symptom 
(primary end point) — hr
0.14 <0.001
Median 2.5 4.6 2.0 12.0
IQR 1.1–6.0 1.8–10.2 1.0–3.5 3.5–25.4
Time to first symptom improvement — hr
According to patient <0.001 <0.001
Median 0.8 16.9 0.8 7.9
IQR 0.5–2.0 3.2–NA 0.4–1.4 1.1–NA
According to investigator <0.001 <0.001
Median 1.0 5.7 1.5 6.9
IQR 0.8–2.0 2.0–11.2 0.7–3.0 4.0–13.8
Time to almost complete relief of symptoms — hr 0.08 <0.001
Median 8.5 19.4 10.0 51.0
IQR 2.5–31.5 10.2–55.7 2.8–23.2 12.0–79.5
Clinically significant relief of the index symptom at 4 hr  
after start of study drug — % (95% CI)
67 (46–84) 46 (28–66)† 0.18 80 (63–92)† 31 (16–48)‡ <0.001
* NA denotes not available, CI confidence interval, and IQR interquartile range.
† Data are missing for one patient.
‡ Data are missing for two patients.
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A composite score on the visual-analogue scale 
was calculated by taking the average of the three 
scores for the main symptoms — abdominal 
pain, cutaneous pain, and cutaneous swelling — 
and defining symptom relief as a 50% reduction 
from the baseline score. On the basis of the com-
posite scores, the median time to symptom relief 
was 2.5 hours with icatibant versus 7.0 hours with 
placebo (P = 0.02) in FAST-1 and 2.0 hours with 
icatibant versus 15.0 hours with tranexamic acid 
(P<0.001) in FAST-2 (Fig. 4 in the Supplementary 
Appendix). Data were censored at 120 hours (the 
end of the observation period) for patients who 
took rescue medication before the onset of symp-
tom relief. After censoring, analysis resulted in a 
time to relief of the index symptom of 2.5 hours 
with icatibant versus 9.0 hours with placebo 
(P = 0.02) in FAST-1 and 2.0 hours with icatibant 
versus 16.0 hours with tranexamic acid (P<0.001) in 
FAST-2 (Table 2 in the Supplementary Appendix).
Several additional post hoc analyses were per-
formed. Most of these also yielded evidence of a 
benefit of icatibant in both trials, although in a few 
analyses the benefit was not significant (Table 3 
in the Supplementary Appendix).
Rescue Medication
In the FAST-1 trial, rescue medication was admin-
istered within the first 12 hours in 3 of the 27 
patients (11%) receiving icatibant, as compared 
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Figure 1. Time to Clinically Significant Relief of the Index Symptom in the FAST-1 and FAST-2 Trials, According to 
Study Group.
The time to clinically significant relief of the index symptom is shown for all FAST-1 patients (Panel A) and all FAST-2 
patients (Panel C) with data, as well as patients in whom the time was 10 hours or less (Panels B and D for FAST-1 
and FAST-2 patients, respectively). Black data points represent individual patients; colored data points represent 
multiple patients at the same time point: green, two patients; blue, three patients; orange, four patients; red, five 
patients; and purple, nine patients. In the FAST-2 trial, data were not available for one patient in the icatibant group 
and two patients in the tranexamic group whose score on the visual-analogue scale was less than 30 mm at baseline.
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with 13 of the 29 patients (45%) receiving placebo, 
and within the first 48 hours in 6 patients (22%) 
and 15 patients (52%), respectively. In the FAST-2 
trial, rescue medication was administered within 
the first 12 hours in 0 of the 36 patients receiving 
icatibant, as compared with 5 of the 38 patients 
(13%) receiving tranexamic acid, and within the 
first 48 hours in 6 patients (17%) and 11 patients 
(29%), respectively.
Laryngeal Attacks
A total of 8 patients in FAST-1 and 3 patients in 
FAST-2 had laryngeal symptoms and received open-
label icatibant; intubation was required in 1 of the 
FAST-2 patients 5 minutes after the icatibant was 
administered. Among these patients, the median 
time to first improvement as reported by the pa-
tient was 0.6 and 1.0 hours, respectively. As report-
ed by an investigator, 7 of the 8 patients in FAST-1 
and 2 of the 3 patients in FAST-2 had no symp-
toms at 4 hours after icatibant administration; the 
remaining patient in each study had mild symp-
toms at 4 hours. A total of 3 of the 8 FAST-1 pa-
tients with laryngeal symptoms received rescue 
medication, within 24 hours after icatibant admin-
istration, for new or recurrent symptoms. None of 
the 3 FAST-2 patients with laryngeal symptoms 
received rescue medication.
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Figure 2. Time to Almost Complete Relief of Symptoms in the FAST-1 and FAST-2 Trials, According to Study Group.
The time to almost complete relief of symptoms is shown for all FAST-1 patients (Panel A) and all FAST-2 patients 
(Panel C) with data, as well as patients in whom the time was 10 hours or less (Panels B and D for FAST-1 and 
FAST-2 patients, respectively). Black data points represent individual patients; colored data points represent multi-
ple patients at the same time point: green, two patients; blue, three patients; orange, four patients; red, five pa-
tients; and purple, nine patients.
The New England Journal of Medicine 
Downloaded from nejm.org at HAUPTBIBLIOTHEK UNIVERSITAET on January 24, 2011. For personal use only. No other uses without permission. 
 Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Icatibant in Hereditary Angioedema
n engl j med 363;6 nejm.org august 5, 2010 539
Adverse Events
Major categories of adverse events occurring in the 
two trials are shown in Table 3; individual events 
classified by organ system are shown in Table 4 in 
the Supplementary Appendix. The most common 
adverse events were recurrent or worsening angio-
edema. Injection-site reactions, which were record-
ed separately from the other adverse events, were 
reported by the majority of patients in each study.
In the FAST-1 trial, 5 patients (9%) had a total 
of 5 adverse events considered to be related to 
the study drug. Of these, four events reported 
by 4 patients (15%) in the icatibant group were 
injection-site pain, abnormal results on a liver-
function test (see the Supplementary Appendix), 
dizziness, and nasal congestion; 1 patient (3%) in 
the placebo group reported one event (injection-
site irritation). In the FAST-2 trial, 5 patients (14%) 
receiving icati bant and 4 patients (11%) receiving 
tranexamic acid had a total of nine and six drug-
related adverse events, respectively. For the 5 pa-
tients in the icatibant group, the events were 
abdominal pain, nausea, and worsening of an 
acute attack of angio edema in 1 patient; asthenia 
in 1 patient; injection-site reactions in 2 patients; 
and two episodes of rash in 1 patient.
No serious adverse events were reported during 
the controlled phase of the FAST-1 study. In the 
FAST-2 study, 5 patients (7%) had a total of 8 seri-
ous adverse events (see the Supplementary Appen-
dix); none were considered to be related to the 
study drug. No patient discontinued either study 
because of an adverse event.
Discussion
We evaluated the effect of icatibant, a bradykinin 
B2 receptor antagonist, in patients with hereditary 
angioedema in two randomized, controlled clinical 
trials. In both trials, icatibant or a comparison 
study drug was administered at the time of pre-
sentation with an acute attack of angioedema. In 
the FAST-1 trial, the primary end point, or the time 
to clinically significant relief of the index symptom, 
was 2.5 hours for patients receiving icatibant and 
4.6 hours for patients receiving placebo, a differ-
ence that was not significant. In the FAST-2 trial, 
the time to clinically significant relief of the index 
symptom was 2.0 hours for the patients receiving 
icatibant and 12.0 hours for the patients receiving 
tranexamic acid, a difference that was significant. 
The time to first improvement, as assessed subjec-
tively, by both the patient and the investigator, was 
significantly faster with icatibant in both trials, al-
though the results of two other prespecified sec-
ondary end points differed between the two trials.
We believe that the rate of the primary end 
point did not differ significantly between the two 
groups in FAST-1 because of the stringent defini-
tion of that end point and its analysis — in par-
ticular, the specification that only the index symp-
tom (and not other symptoms) be assessed in 
defining symptom relief and the inclusion of data 
from patients in the placebo group who received 
rescue medication early. In a post hoc analysis that 
censored data from patients who received rescue 
medication, a significant benefit of icatibant as 
compared with placebo was shown (Table 2 in the 
Supplementary Appendix). This was also true for 
an exploratory analysis of all three index symp-
toms together, even when the end point of time to 
symptom relief was conservatively defined as a re-
duction of the baseline score on the visual-ana-
logue scale of more than 50% (Fig. 4 in the Supple-
mentary Appendix). On the basis of the published 
literature and clinical experience, it is very un-
likely that the difference in results regarding the 
primary end point between FAST-1 and FAST-2 is 
due to a harmful effect of tranexamic acid.
Table 3. Adverse Events in the Safety Populations of the FAST-1 and FAST-2 
Trials, According to Study Group.
Adverse Event FAST-1 FAST-2
Icatibant 
(N = 27)
Placebo 
(N = 29)
Icatibant 
(N = 36)
Tranexamic 
Acid 
(N = 38)
no. of patients (%)
Any adverse event 12 (44) 19 (66) 19 (53) 16 (42)
Drug-related adverse event* 4 (15) 1 (3) 5 (14) 4 (11)
Serious adverse event† 0 0 4 (11) 1 (3)
Injection-site reaction 26 (96) 8 (28) 35 (97) 10 (26)
* Drug-related adverse events in the icatibant groups were as follows: in the 
FAST-1 trial, injection-site pain in one patient, abnormal results on a liver-
function test in one patient, dizziness in one patient, and nasal congestion in 
one patient; and in the FAST-2 trial, abdominal pain, nausea, and worsening 
of hereditary angioedema in one patient; asthenia in one patient; worsening 
of an acute attack of angioedema in one patient; injection-site reaction and 
two episodes of rash in one patient; and injection-site reaction in one patient.
† Serious adverse events in the icatibant group in the FAST-2 trial were as fol-
lows: gastroenteritis and hypertensive crisis in one patient, laryngeal attack of 
angioedema in one patient, abdominal attack of angioedema in one patient, 
cholelithiasis in one patient, and laryngeal attack of angioedema requiring in-
tubation in one patient. None were considered to be related to icatibant.
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A further possible explanation is that the FAST-
1 trial was underpowered to detect a clinically rel-
evant difference in the primary end point. As not-
ed, the trial was powered on the basis of the 
assumption that the median difference in the time 
to clinically significant relief of the index symp-
tom would be 5.5 hours; the actual difference in 
median values was 2.1 hours. This difference, if 
real, would be clinically important.
No serious drug-related adverse events were 
reported in either trial, and no patient discontin-
ued either study owing to an adverse event. Al-
though most patients receiving icatibant had an 
injection-site reaction, these were generally mild or 
moderate in severity and short-lived and resolved 
spontaneously. Despite the theoretical concern that 
icatibant might alter blood pressure owing to an-
tagonism of the vasodilating properties of brady-
kinin,19 the use of icatibant did not increase blood 
pressure and had no effect on heart rate. The fact 
that recurrent or worsening angioedema was the 
most commonly reported adverse event suggests 
that, in clinical practice, additional medication 
(either another dose of icatibant or another agent) 
would likely be necessary in some patients to 
achieve complete control of symptoms.
In summary, we evaluated the effect of icati-
bant for the treatment of acute attacks of angio-
ede ma in patients with hereditary angioedema. 
In the FAST-1 trial, there was a nonsignificant 
difference in the primary end point for patients 
given icatibant and patients given placebo. In the 
FAST-2 trial, the time to clinically significant re-
lief of the index symptom was significantly 
shorter for patients given icatibant than for pa-
tients given tran ex amic acid. The early use of 
rescue medication may have obscured a benefit 
of icatibant in the FAST-1 trial. To clarify the 
effect of icatibant as compared with placebo in 
the treatment of acute attacks of angioedema, a 
larger trial will be necessary.
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